Search results
Jul 1, 2013 · ASTELLAS PHARMA SINGAPORE PTE. LTD. was incorporated on 1 July 2013 (Monday) as a Private Company Limited by Shares in Singapore. The Company current operating status is live with registered address at SUNTEC TOWER FOUR. The Company principal activity is in WHOLESALE OF MEDICINAL AND PHARMACEUTICAL PRODUCTS (WESTERN).
May 31, 2024 · Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha) .
Astellas was established in 2005 through merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical CO., Ltd. and has a rich history... Vision & Strategy On the forefront of healthcare change to turn innovative science into value for patients.
Astellas Pharma Singapore Pte. Ltd. 6 Temasek Boulevard, #26-03/05 Suntec Tower Four, Singapore 038986. Tel: +65-6500-9330. Fax: +65-6836-5350. Access Map (Google Maps)
Astellas aims to stand on the forefront of healthcare change, turning innovative science into VALUE for patients and will continually strive to fulfill the expectations of our stakeholders and society.
Astellas Pharma is a pharmaceutical company conducting business in approximately 70 countries around the world. | At Astellas, we strive to be a cutting-edge, value-driven life science innovator.
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic.
Astellas Pharma Inc (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, cancer, nephrology, infectious diseases, and metabolic diseases, immunodeficiency, and transplantation.
May 12, 2023 · Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause. VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause. TOKYO, May 12, 2023 / PRNewswire / -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki ...
